Evolus (EOLS) Stock Price, News & Analysis

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Evolus in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" EOLS shares.
View EOLS analyst ratings or view top-rated stocks.

3 brokerages have issued twelve-month target prices for Evolus' shares. Their EOLS share price targets range from $16.00 to $27.00. On average, they expect the company's stock price to reach $20.60 in the next year. This suggests a possible upside of 79.8% from the stock's current price.
View analysts price targets for EOLS or view top-rated stocks among Wall Street analysts.

Evolus' stock was trading at $10.53 at the beginning of 2024. Since then, EOLS stock has increased by 8.8% and is now trading at $11.46.
View the best growth stocks for 2024 here.

Evolus saw a decline in short interest in March. As of March 31st, there was short interest totaling 4,650,000 shares, a decline of 6.6% from the March 15th total of 4,980,000 shares. Based on an average daily trading volume, of 657,700 shares, the days-to-cover ratio is currently 7.1 days. Approximately 9.8% of the shares of the stock are sold short.
View Evolus' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024.
View our EOLS earnings forecast.

Evolus, Inc. (NASDAQ:EOLS) announced its quarterly earnings data on Thursday, March, 7th. The company reported ($0.20) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.15) by $0.05. The business earned $61 million during the quarter, compared to analyst estimates of $61.14 million.

ETFs with the largest weight of Evolus (NASDAQ:EOLS) stock in their portfolio include SPDR S&P Pharmaceuticals ETF (XPH).Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL).

Evolus issued an update on its FY 2024 earnings guidance on Friday, March, 8th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $255.0 million-$265.0 million, compared to the consensus revenue estimate of $261.2 million.

1 employees have rated Evolus Chief Executive Officer David Moatazedi on Glassdoor.com. David Moatazedi has an approval rating of 100% among the company's employees. This puts David Moatazedi in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Evolus investors own include Celadon Group (CGI), ADMA Biologics (ADMA), Chesapeake Energy (CHKAQ), Matinas BioPharma (MTNB), Advanced Micro Devices (AMD), Dynavax Technologies (DVAX), Sorrento Therapeutics (SRNE), Aldeyra Therapeutics (ALDX), Organigram (OGI) and Bionano Genomics (BNGO).

Evolus (EOLS) raised $65 million in an IPO on Thursday, February 8th 2018. The company issued 5,000,000 shares at $12.00-$14.00 per share. Cantor and Mizuho Securities acted as the underwriters for the IPO and SunTrust Robinson Humphrey and JMP Securities were co-managers.

Evolus' stock is owned by many different retail and institutional investors. Top institutional investors include Los Angeles Capital Management LLC (0.24%). Insiders that own company stock include Alphaeon 1 Llc, Crystal Muilenburg, David Moatazedi, David N Gill, Karah Herdman Parschauer, Lauren P Silvernail, Medytox Inc, Robert Hayman, Rui Avelar, Sandra Beaver and Vikram Malik.
View institutional ownership trends.

Shares of EOLS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.